These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 17096757

  • 1. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy.
    Schachter AD, Benfield MR, Wyatt RJ, Grimm PC, Fennell RS, Herrin JT, Lirenman DS, McDonald RA, Munoz-Arizpe R, Harmon WE.
    Pediatr Transplant; 2006 Dec; 10(8):914-9. PubMed ID: 17096757
    [Abstract] [Full Text] [Related]

  • 2. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol.
    Schachter AD, Meyers KE, Spaneas LD, Palmer JA, Salmanullah M, Baluarte J, Brayman KL, Harmon WE.
    Pediatr Transplant; 2004 Apr; 8(2):171-7. PubMed ID: 15049798
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
    Chen KH, Lee CY, Wu FL, Yang CY, Yeh CC, Hu RH, Tsai MK.
    J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
    [Abstract] [Full Text] [Related]

  • 6. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 15; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 8. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F, Christians U, Smith L, Wellen JR, Kaplan B.
    Transpl Immunol; 2014 Jun 15; 31(1):22-32. PubMed ID: 24861504
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar 15; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 10. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb 15; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 11. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration.
    McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS.
    Ther Drug Monit; 2002 Jun 15; 24(3):346-50. PubMed ID: 12021624
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
    Chueh SC, Wang SM, Lai MK, Chen J.
    Transplant Proc; 2004 Sep 15; 36(7):2058-9. PubMed ID: 15518745
    [Abstract] [Full Text] [Related]

  • 13. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R.
    Liver Transpl; 2000 Nov 15; 6(6):734-40. PubMed ID: 11084060
    [Abstract] [Full Text] [Related]

  • 14. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan 15; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB, Grimm EM.
    Am J Kidney Dis; 2001 Oct 15; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [Abstract] [Full Text] [Related]

  • 16. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C, Coentrão L, Bustorff M, Patrício E, Sampaio S, Santos J, Oliveira G, Pestana M.
    Clin Transplant; 2011 Oct 15; 25(4):E401-5. PubMed ID: 21457330
    [Abstract] [Full Text] [Related]

  • 17. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.
    Wu FL, Tsai MK, Chen RR, Sun SW, Huang JD, Hu RH, Chen KH, Lee PH.
    Pharmacotherapy; 2005 May 15; 25(5):646-53. PubMed ID: 15899725
    [Abstract] [Full Text] [Related]

  • 18. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.
    Cattaneo D, Cortinovis M, Baldelli S, Gotti E, Remuzzi G, Perico N.
    J Clin Pharmacol; 2009 Jul 15; 49(7):773-81. PubMed ID: 19491334
    [Abstract] [Full Text] [Related]

  • 19. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine.
    Figurski MJ, Nawrocki A, Pescovitz MD, Bouw R, Shaw LM.
    Ther Drug Monit; 2008 Aug 15; 30(4):445-55. PubMed ID: 18641543
    [Abstract] [Full Text] [Related]

  • 20. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Aug 15; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.